



Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

Nicola L. Lawson¹ · Carly I. Dix² · Paul W. Scorer¹ · Christopher J. Stubbs³ · Edmond Wong² · Liam Hutchinson⁴ · Eileen J. McCall⁵ · Marianne Schimpf³ · Emma DeVries² · Jill Walker⁶ · Gareth H. Williams⁷ · James Hunt² · Craig Barker¹

Published online: 22 October 2019

© The Author(s) 2019. This article is published with open access

Correction to: Modern Pathology

<https://doi.org/10.1038/s41379-019-0372-z>

This article was erroneously published with standard licence and copyright, but it is in fact published with open access, so has a CC BY licence and the copyright line is ‘The Author(s)’. This has been updated in the original article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

The original article can be found online at <https://doi.org/10.1038/s41379-019-0372-z>.

✉ Craig Barker
craig.barker@astrazeneca.com

¹ Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, UK

² Antibody Discovery and Protein Engineering (ADPE), R&D, AstraZeneca, Cambridge, UK

³ Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

⁴ Spirogen, AstraZeneca, London, UK

⁵ FM Operations, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

⁶ Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, UK

⁷ Oncologica UK Ltd, Cambridge, UK